What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof?
Featuring Tina Bhutani, MD, MAS |
CEO, Synergy Dermatology
Associate Clinical Professor of Dermatology
University of California, SF
San Francisco, CA
Related CME
Related Media
Powered by Polaris TM